Aspiration thrombectomy in ST-elevation myocardial infarction

Sanjit S. Jolly1*, MD, MSc; Kari Niemela2, MD

1. Department of Medicine, McMaster University, Hamilton, Ontario, Canada; 2. Tampere Heart Hospital, Tampere, Finland

KEYWORDS

- myocardial infarction
- primary percutaneous coronary intervention
- ST-elevation myocardial infarction
- thrombectomy

Abstract

The major challenge in the treatment of ST-elevation myocardial infarction (STEMI) is not only restoration of normal coronary blood flow but also microvascular perfusion. In fact, both electrocardiographic (ST segment resolution) and angiographic measures of myocardial perfusion (myocardial blush grade) have been shown to predict mortality after primary percutaneous coronary intervention (PPCI). Initial enthusiasm for manual thrombectomy arose after the apparent mortality benefit observed in the TAPAS trial (N=1,071). Meta-analyses of small trials suggest that manual thrombectomy improves epicardial and microvascular perfusion with trends towards benefit for survival. On the other hand, meta-analyses of small trials of mechanical thrombectomy show improvement in ST resolution without an effect on survival. Recently, the TASTE trial (N=7,244) showed no reduction in mortality with manual thrombectomy but trends toward reduction in rates of rehospitalisation for recurrent MI and stent thrombosis. The interpretation of TASTE should be cautious given that the trial had a much lower than expected mortality, and modest but important treatment effects cannot be excluded (20-30%). The largest trial, the ongoing TOTAL trial (N=10,700), will help determine the effect of manual thrombectomy for important clinical outcomes. A planned individual patient meta-analysis of the TOTAL and TASTE trials will have approximately 17,000 patients to examine the effect on clinical outcomes.

DOI: 10.4244/EIJV10STA7

*Corresponding author: Rm. C3-118, DBCSVRI Building, Hamilton General Hospital, 237 Barton St. East, Hamilton, Ontario, L8L 2X2, Canada. E-mail: sanjit.jolly@phri.ca

Scientific rationale for thrombectomy

ST-elevation myocardial infarction is characterised by plaque rupture and occlusion of the infarct artery with thrombus. Modern primary PCI is very effective in restoring epicardial flow in the infarct artery but a significant limitation is distal embolisation of thrombus and obstruction of the microvasculature¹⁻³.

Microvascular perfusion in STEMI, as measured by angiographic myocardial blush grade (MBG) and electrocardiographic ST-segment resolution, has clearly been linked to mortality after primary PCI (**Figure 1**)³. About one third of patients who have undergone PPCI have impaired microvascular perfusion despite restoration of normal epicardial flow, and they have a significantly increased mortality. Furthermore, thrombus burden during primary PCI has been linked to mortality⁴. In an analysis of 812 consecutive STEMI patients, large as compared to small thrombus burden patients had higher mortality (12.9% vs. 7.8% at one year, p=0.025), higher rates of stent thrombosis (8.2% vs. 1.3%, p=0.001) and lower rates of grade 3 MBG (35% vs. 53%, p<0.001)⁴.




Figure 1. *Myocardial blush grade and mortality after PPCI.* (*Reproduced with permission*³).

Thrombectomy has the potential to reduce distal embolisation and improve microvascular perfusion during PPCI. In addition, thrombectomy in STEMI allows better visualisation of the infarct artery and lesion by removing thrombus, which is useful for treating the culprit lesion and determining stent length. Residual thrombus at the target lesion may be a nidus for stent thrombosis, and therefore thrombus removal may lower the risk of stent thrombosis. Furthermore, removal of thrombus may prevent late stent malapposition and subsequent stent thrombosis. There is an intuitive biologic rationale for thrombectomy based on these potential benefits.

Types of thrombectomy

The two main types of thrombectomy are manual aspiration and mechanical rheolytic thrombectomy. In clinical practice, thrombectomy is most commonly performed using simple manual aspiration devices with a tapered microcatheter attached to a syringe. Mechanical thrombectomy (e.g., using the AngioJet[®] Ultra thrombectomy system; Bayer Healthcare/MEDRAD, Inc., Warrendale, PA, USA) is characterised by active mechanical suction and high-velocity saline jets to break up thrombus. Manual thrombectomy catheters are significantly less expensive and simpler to use than mechanical thrombectomy devices.

Common predictors for failure of successful thrombectomy with manual thrombectomy devices include tortuosity of the coronary artery, a calcified lesion, and a bifurcation lesion⁵. Failure to cross or reach the lesion has been observed in about 10% of the patients⁵. No aspirate has been observed in about 10-20%^{2,5,6}. Finally, manual thrombectomy devices may not be able to remove very large thrombi. Other potential complications of thrombus aspiration include dissection of the coronary artery and thrombus dislodgement during retrieval of the aspiration catheter which may embolise thrombus to the non-infarct vessel. Finally, operator technique can impact on the success of thrombus aspiration⁷.

Table 1. Optimal technique for manual thrombectomy.

- 1. Start aspiration prior to crossing lesion.
- 2. Ensure adequate guide support to reach target lesion with aspiration catheter.
- 3. If aspiration slows, change aspiration syringe as syringe can lose suction quickly.
- If suction stops suddenly during aspiration despite changing syringe, remove aspiration catheter and flush outside body as tip may be obstructed with large thrombus.
- 5. Ensure guide engagement with coronary ostium when removing thrombectomy catheter to avoid losing thrombus which could embolise to cerebral vasculature and cause stroke.
- Aspirate guide catheter after thrombectomy to remove air or residual thrombus. Thrombus embolised down non-infarct territory can be catastrophic.
- If unable to cross lesion with thrombectomy catheter, consider small diameter balloon dilation and then re-attempt

The newest generation of aspiration catheters has achieved improved deliverability by using a stylet-based system (e.g., Export Advance[™] aspiration catheter; Medtronic, Minneapolis, MN, USA; Eliminate[™] aspiration catheter; Terumo Corp., Tokyo, Japan). These devices may improve the ability to cross tortuosity and retrieve thrombus.

Evidence for manual thrombectomy

Meta-analyses of randomised trials have demonstrated that manual thrombectomy improves epicardial and microvascular perfusion and reduces distal embolisation in STEMI^{8,9}. The first large trial of manual thrombectomy was the TAPAS (N=1,071, single-centre trial) which randomised patients to the Export aspiration catheter (Medtronic, Minneapolis, MN, USA), vs. PCI alone in STEMI². They showed an improvement in primary outcome of MBG 0 or 1 (17% vs. 26%, p<0.001), but this modest change in a surrogate outcome led to a near 50% reduction in cardiac mortality at one year $(3.6\% \text{ vs. } 6.7\%, p=0.020)^{2.10}$.

The TAPAS trial led to the design of the TASTE trial (N=7,244), a registry-based randomised trial in Sweden comparing manual thrombectomy vs. PCI alone in patients with STEMI¹¹. The primary outcome of mortality was not different (2.8% vs. 3.0%, p=0.63), but there were trends towards reduction in re-hospitalisation for MI (0.5% vs. 0.9%, p=0.09) and stent thrombosis (0.2% vs. 0.5%, p=0.06). Importantly, despite being the largest trial ever performed in thrombectomy, the trial had fewer deaths than planned (213 vs. planned 456), so the trial cannot exclude realistic but important reductions in mortality (20-30%). Finally, the one year results of TASTE are not yet available and will provide important long-term data on thrombectomy.

Future ongoing trials

The TOTAL trial is a randomised trial of nearly 11,000 patients which is designed to determine if routine manual thrombectomy vs. PCI alone can reduce the composite of cardiovascular death, MI, shock or class IV heart failure at 180 days¹². The trial is an event-driven trial and is powered to detect a 20% relative risk reduction in primary outcome. There are important substudies of the TOTAL trial, including the optical coherence tomography (OCT) substudy that will compare thrombus burden prior to stenting in thrombectomy group vs. PCI alone and provide insights into the effective-ness of current technology to remove thrombus. Finally, there is a planned individual patient meta-analysis of both the TASTE and TOTAL trials and this will have significantly more power for the outcome of mortality with approximately 17,000 patients.

Another question is, does selective thrombectomy in patients with a high thrombus burden compared to no thrombectomy improve clinical outcomes? The subgroup analysis of TASTE found no mortality benefit in patients with high thrombus burden $(n=2,216)^{11}$; however, further subgroup analysis from a larger trial, TOTAL, and individual patient meta-analyses will have much more power to examine this question.

Evidence for mechanical thrombectomy

One significant limitation of manual aspiration is its inability to remove large volume thrombus. Mechanical thrombectomy, if more effective at thrombus removal, may be postulated to be particularly beneficial in patients with large thrombus. A randomised trial of manual vs. mechanical thrombectomy demonstrated less residual thrombus with mechanical thrombectomy as measured by OCT¹³. The two largest trials of mechanical thrombectomy vs. PCI alone show divergent results. The AIMI trial (N=480) demonstrated, in an all-comer STEMI population, that the AngioJet (Bayer Healthcare/MEDRAD, Inc.) was associated with increased infarct size and a higher rate of mortality compared to PCI alone¹⁴. On the other hand, in selected patients with high thrombus burden, the JETSTENT trial (N=501) demonstrated improved ST resolution and MACE but no difference in mortality¹⁵. In patients with high thrombus burden, a large-scale trial is needed with mechanical thrombectomy to determine its benefit on clinical outcomes.

Based on the current evidence, mechanical thrombectomy remains a bail-out option in cases of very high thrombus burden not responsive to manual thrombectomy or other measures.

Guidelines

The ESC provides a class IIa recommendation for routine manual thrombectomy during STEMI¹⁶. On the other hand, there are no ESC guideline recommendations regarding mechanical thrombectomy.

Summary and recommendations for clinical practice

Manual thrombectomy remains a useful tool during STEMI PCI but further trials will help determine its effect on important clinical events. In the meantime, manual thrombectomy should be considered simply another tool in the PCI toolkit to optimise an angiographic result during PPCI. Selective use of these devices in patients with large thrombus burden to facilitate stent placement appears to be a logical approach until further data are available. Finally, regarding mechanical thrombectomy, future trials are needed to determine the benefit/risk ratio in patients with high thrombus burden.

Conflict of interest statement

S. Jolly reports grant support from Medtronic, and honoraria from AstraZeneca and St. Jude Medical. K Niemela has no conflicts of interest to declare.

References

1. Henriques JP, Zijlstra F, Ottervanger JP, de Boer MJ, van 't Hof AW, Hoorntje JC, Suryapranata H. Incidence and clinical significance of distal embolization during primary angioplasty for acute myocardial infarction. *Eur Heart J.* 2002;23:1112-7.

2. Svilaas T, Vlaar PJ, van der Horst IC, Diercks GF, de Smet BJ, van den Heuvel AF, Anthonio RL, Jessurun GA, Tan ES, Suurmeijer AJ, Zijlstra F. Thrombus aspiration during primary percutaneous coronary intervention. *N Engl J Med.* 2008;358:557-67.

3. Stone GW, Peterson MA, Lansky AJ, Dangas G, Mehran R, Leon MB. Impact of normalized myocardial perfusion after successful angioplasty in acute myocardial infarction. *JAm Coll Cardiol.* 2002;39:591-7.

4. Sianos G, Papafaklis MI, Daemen J, Vaina S, van Mieghem CA, van Domburg RT, Michalis LK, Serruys PW. Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: the importance of thrombus burden. *J Am Coll Cardiol.* 2007;50:573-83.

5. Vink MA, Kramer MC, Li X, Damman P, Rittersma SZ, Koch KT, van der Wal AC, Tijssen JG, de Winter RJ. Clinical and angiographic predictors and prognostic value of failed thrombus aspiration in primary percutaneous coronary intervention. *JACC Cardiovasc Interv.* 2011;4:634-42.

6. Silva-Orrego P, Colombo P, Bigi R, Gregori D, Delgado A, Salvade P, Oreglia J, Orrico P, de Biase A, Piccalo G, Bossi I, Klugmann S. Thrombus aspiration before primary angioplasty improves myocardial reperfusion in acute myocardial infarction: the DEAR-MI (Dethrombosis to Enhance Acute Reperfusion in Myocardial Infarction) study. *J Am Coll Cardiol.* 2006;48:1552-9.

7. Vlaar PJ, de Smet BJ, van den Heuvel AF, Anthonio RL, Jessurun GA, Tan ES, Hillege HL, Zijlstra F. Operator dependence of outcome after primary percutaneous coronary intervention. *EuroIntervention*. 2011;6:760-7.

8. Mongeon FP, Belisle P, Joseph L, Eisenberg MJ, Rinfret S. Adjunctive thrombectomy for acute myocardial infarction: A bayesian meta-analysis. *Circ Cardiovasc Interv.* 2010;3:6-16.

9. Bavry AA, Kumbhani DJ, Bhatt DL. Role of adjunctive thrombectomy and embolic protection devices in acute myocardial infarction: a comprehensive meta-analysis of randomized trials. *Eur Heart J.* 2008;29:2989-3001.

10. Vlaar PJ, Svilaas T, van der Horst IC, Diercks GF, Fokkema ML, de Smet BJ, van den Heuvel AF, Anthonio RL, Jessurun GA, Tan ES, Suurmeijer AJ, Zijlstra F. Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1-year follow-up study. *Lancet.* 2008;371:1915-20.

11. Frobert O, Lagerqvist B, Olivecrona GK, Omerovic E, Gudnason T, Maeng M, Aasa M, Angeras O, Calais F, Danielewicz M, Erlinge D, Hellsten L, Jensen U, Johansson AC, Karegren A, Nilsson J, Robertson L, Sandhall L, Sjogren I, Ostlund O, Harnek J, James SK; TASTE Trial. Thrombus aspiration during ST-segment elevation myocardial infarction. *N Engl J Med.* 2013;369:1587-97.

12. Jolly SS, Cairns J, Yusuf S, Meeks B, Shestakovska O, Thabane L, Niemela K, Steg PG, Bertrand OF, Rao SV, Avezum A, Cantor WJ, Pancholy SB, Moreno R, Gershlick A, Bhindi R, Welsh RC, Cheema AN, Lavi S, Rokoss M, Dzavik V. Design and rationale of the TOTAL trial: a randomized trial of routine

aspiration ThrOmbecTomy with percutaneous coronary intervention (PCI) versus PCI ALone in patients with ST-elevation myocardial infarction undergoing primary PCI. *Am Heart J.* 2014;167: 315-21.

13. Parodi G, Valenti R, Migliorini A, Maehara A, Vergara R, Carrabba N, Mintz GS, Antoniucci D. Comparison of manual thrombus aspiration with rheolytic thrombectomy in acute myocardial infarction. *Circ Cardiovasc Interv.* 2013;6:224-30.

14. Ali A, Cox D, Dib N, Brodie B, Berman D, Gupta N, Browne K, Iwaoka R, Azrin M, Stapleton D, Setum C, Popma J; AIMI Investigators. Rheolytic thrombectomy with percutaneous coronary intervention for infarct size reduction in acute myocardial infarction: 30-day results from a multicenter randomized study. *J Am Coll Cardiol.* 2006;48:244-52.

15. Migliorini A, Stabile A, Rodriguez AE, Gandolfo C, Rodriguez Granillo AM, Valenti R, Parodi G, Neumann FJ, Colombo A, Antoniucci D; JETSTENT Trial Investigators. Comparison of AngioJet rheolytic thrombectomy before direct infarct artery stenting with direct stenting alone in patients with acute myocardial infarction. The JETSTENT trial. *J Am Coll Cardiol.* 2010;56: 1298-306.

16. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van 't Hof A, Widimsky P, Zahger D. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Eur Heart J.* 2012;33:2569-619.